Inactive Instrument

GTx, Inc. Stock Nasdaq

US40052B1089

Biotechnology & Medical Research

Analysts' recommendations : GTx, Inc.

12/09/24	Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy	MT
15/04/24	HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating	MT
04/12/23	Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2	MT
18/09/23	HC Wainwright Upgrades Oncternal Therapeutics to Buy From Neutral, Price Target is $2	MT
04/04/23	Maxim Downgrades Oncternal Therapeutics to Hold From Buy	MT

More recommendations

Managers and Directors : GTx, Inc.

Manager	Title	Age	Since
Richard Vincent DFI	Director of Finance/CFO	63	01/04/2017
Yisrael Katz CTO	Chief Tech/Sci/R&D Officer	-	01/07/2023
Rajesh Krishnan CTO	Chief Tech/Sci/R&D Officer	53	-

Director	Title	Age	Since
David Hale CHM	Chairman	77	01/12/2018
Dan Kisner BRD	Director/Board Member	79	07/06/2019
William LaRue BRD	Director/Board Member	75	01/12/2017

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GTX, INC.	-2.05%	+738.04%	-	-	1.56M
LONZA GROUP AG	-1.23%	-1.91%	+0.98%	+17.94%	49.81B
REVOLUTION MEDICINES, INC.	-1.11%	-2.84%	+420.04%	+505.15%	44.06B
IQVIA HOLDINGS INC.	-0.21%	+0.37%	+36.88%	+17.32%	42.99B
BEONE MEDICINES AG	-1.95%	-3.33%	+8.29%	+73.25%	40.88B
CELLTRION, INC.	-0.94%	-1.77%	+18.34%	+46.84%	33.11B
MEDPACE HOLDINGS, INC.	-1.11%	-4.20%	+25.49%	+119.78%	16.58B
ASCENDIS PHARMA A/S	+6.10%	+4.40%	-	-	17.27B
EUROFINS SCIENTIFIC SE	+0.25%	-0.98%	+11.91%	+27.62%	14.63B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.12%	-3.46%	+76.50%	+39.37%	13.76B
Average	-0.34%	-1.37%	+74.80%	+105.91%	30.34B
Weighted average by Cap.	-0.57%	-1.50%	+88.88%	+122.63%

See all sector performances

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâ€™s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	1.56M 1.34M 1.26M 1.15M 2.16M 148M 2.18M 14.93M 5.81M 75.2M 5.85M 5.72M 249M	P/E 2022	-1.19x	P/E 2023	-0.8x
Enterprise Value	-32.38M -27.88M -26.18M -23.89M -44.89M -3.08B -45.21M -310M -121M -1.56B -122M -119M -5.17B	EV / Sales 2022	-4.9x	EV / Sales 2023	-2.95x
Free-Float	90.77%	Yield 2022 *	-	Yield 2023	-

01/07/25	Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
01/07/25	Oncternal Therapeutics, Inc. Announces Management Changes	CI
05/12/24	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from S&P TMI Index	CI
02/12/24	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from NASDAQ Composite Index	CI
25/11/24	Top Premarket Decliners	MT
07/11/24	Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
23/10/24	Oncternal Therapeutics Continues to Explore Strategic Alternatives	CI
22/10/24	Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	CI
13/09/24	Oncternal Therapeutics, Inc. Announces Discontinue Its Clinical Trials Evaluating ONCT-534	CI
13/09/24	Oncternal Therapeutics, Inc. Announces Workforce Reduction	CI
13/09/24	Oncternal Therapeutics, Inc. Announces Cessation of Salim Yazji as Chief Medical Officer, Effective as of October 1, 2024	CI
13/09/24	Sector Update: Health Care Stocks Rise in Thursday Trading	MT
12/09/24	Oncternal Therapeutics Announces Exploration of Strategic Alternatives	CI

08/03/25	Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC	AQ
25/11/24	Oncternal Therapeutics : Failure to Satisfy Listing Rule Form 8 K	PU
22/10/24	Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	AQ
12/09/24	Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives	AQ
09/08/24	Oncternal Therapeutics: Q2 Earnings Snapshot	AQ

	2022	2023
Net sales	1.49M 1.28M 1.2M 1.1M 2.07M 142M 2.08M 14.27M 5.55M 71.89M 5.59M 5.47M 238M	785K 676K 635K 579K 1.09M 74.69M 1.1M 7.52M 2.93M 37.88M 2.95M 2.88M 125M
Net income	-44.17M -38.03M -35.71M -32.6M -61.24M -4.2B -61.67M -423M -165M -2.13B -166M -162M -7.06B	-39.48M -33.99M -31.92M -29.13M -54.73M -3.76B -55.12M -378M -147M -1.9B -148M -145M -6.31B
Net Debt	-63.64M -54.79M -51.45M -46.96M -88.22M -6.06B -88.86M -610M -237M -3.07B -239M -234M -10.17B	-33.94M -29.22M -27.44M -25.04M -47.05M -3.23B -47.39M -325M -126M -1.64B -127M -125M -5.42B

GTx, Inc. Stock Nasdaq

Stocks

US40052B1089

Biotechnology & Medical Research

Valuation : GTx, Inc.

Latest news : GTx, Inc.

Analysts' recommendations : GTx, Inc.

Press Releases : GTx, Inc.

Quotes and Performance

Managers and Directors : GTx, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile